Matrixx Shares Spike On Zicam Rumor Print
By Staff and Wire Reports   
Thursday, 03 September 2009 13:00
Shares of Matrixx Initiatives, Inc. (NASDAQ:MTXX) spiked on Thursday afternoon based on rumors that the company has submitted a new Zicam formula to the FDA.

The FDA on June 16, 2009 warned MTXX that two of its cold remedies may have been causing a loss of smell.

Prior to the June warning by the FDA, in which the company warned consumers not to use certain Zicam nasal products, Matrixx shares sank from over $20 per share.

MTXX September option implied volatility is at 135, October is at 151, January is at 126; above its 26-week average of 91, according to Track Data, suggesting large price movement.


"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus